Difference between revisions of "User talk:Z3332250"
From Embryology
| Line 1: | Line 1: | ||
=Articles to read:= | =Articles to read:= | ||
| + | =="""Carido"""== | ||
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/?tool=pmcentrez | *http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/?tool=pmcentrez | ||
*http://www.ncbi.nlm.nih.gov/pubmed/2940284 | *http://www.ncbi.nlm.nih.gov/pubmed/2940284 | ||
| Line 6: | Line 7: | ||
*http://www.ncbi.nlm.nih.gov/pubmed/2944367 | *http://www.ncbi.nlm.nih.gov/pubmed/2944367 | ||
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez | *http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez | ||
| + | |||
| + | ---- | ||
| + | <ref name="PMID19283344"><pubmed>19283344</pubmed></ref> | ||
| + | |||
| + | =Treatment= | ||
| + | |||
| + | friedreich Ataxia (FA) a progressive neurological congenital disorder<ref name="PMID19283349"><pubmed>19283349</pubmed></ref>, wtih no treatment identified only possible pharmaceutics which can reduce the progression of FA however not significantly. Whereas significant treatment poties of FA or reduction in progression are the following: | ||
| + | |||
| + | *Iron-chelation | ||
| + | **deferoxamine | ||
| + | *Antioxidants: | ||
| + | **Idebenone | ||
| + | **Coenzyme Q10 | ||
Revision as of 00:25, 7 September 2011
Articles to read:
"""Carido"""
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/?tool=pmcentrez
- http://www.ncbi.nlm.nih.gov/pubmed/2940284
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/pdf/v081p00141.pdf
- http://www.ncbi.nlm.nih.gov/pubmed/2944367
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez
[1]
Treatment
friedreich Ataxia (FA) a progressive neurological congenital disorder[2], wtih no treatment identified only possible pharmaceutics which can reduce the progression of FA however not significantly. Whereas significant treatment poties of FA or reduction in progression are the following:
- Iron-chelation
- deferoxamine
- Antioxidants:
- Idebenone
- Coenzyme Q10
